Avidity to raise $400M; Sato pays Arcutis $25M upfront to license topical roflumilast in Japan

Plus, news about Xen­cor, Ot­su­ka, Type­writer Ther­a­peu­tics, Cas­sa­va Sci­ences, En­ver­ic Bio­sciences, Viking Ther­a­peu­tics and Janux Ther­a­peu­tics:

Next up in the PIPE bo­nan­za: RNA com­pa­ny Avid­i­ty Bio­sciences ex­pects to raise $400 mil­lion from sell­ing stock to more than nine pri­vate in­vestors, RA Cap­i­tal, RTW In­vest­ments and Far­al­lon. Sev­er­al biotech com­pa­nies have raised mon­ey via pri­vate in­vest­ment in pub­lic eq­ui­ty this week. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.